In recent years, immune checkpoint inhibitors (ICIs), especially for programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, have brought new hope to SCLC patients (Facchinetti et al., 2020). Here, PDCD1 is linked to small cell lung carcinoma.